文献速递其他结缔组织病

托珠单抗治疗系统性硬化症的安全性与有效性:法意多中心研究

Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study.
PubMed 文献 · RMD Open · 2026-06-09

该回顾性多中心队列纳入197例接受托珠单抗治疗的系统性硬化症患者,评估真实世界安全性与有效性。托珠单抗引入后,间质性肺病进展者比例从43%降至24%,皮肤硬化、指端溃疡、关节炎活动及心脏生物标志物均改善,感染为最常见不良事件(22.8%)。

要点

  • 托珠单抗引入后%pFVC稳定,ILD进展者比例由43%降至24%(p=0.015)。
  • 弥漫性皮肤型患者mRSS在12和24个月显著下降,指端溃疡与关节炎活动改善。
  • 感染为最常见不良事件(22.8%),32%患者因疗效不足等原因停药。

核心结论

  • 在大型真实世界队列中,托珠单抗安全性可接受,并在系统性硬化症多个领域表现出一致获益,支持其作为特定患者的潜在疾病修饰治疗。

研究设计与样本

  • 法国-意大利15家转诊中心开展的回溯性分析,纳入197例接受托珠单抗治疗的系统性硬化症患者(88%女性,中位年龄57岁,中位病程9年,67%抗拓扑异构酶I阳性)。

主要发现

  • 在系统性硬化症相关间质性肺病中,%pFVC从托珠单抗前12个月至基线显著下降(81%至77%;p=0.003),托珠单抗引入后稳定。
  • ILD进展者比例从43%降至24%(p=0.015)。
  • 弥漫性皮肤型患者mRSS在12和24个月显著下降,指端溃疡、关节炎活动及心脏生物标志物亦改善。
  • 感染为最常见不良事件(22.8%),32%患者停用托珠单抗,主要因疗效不足。
  • 肺动脉高压和高龄预测托珠单抗治疗失败,而CRP升高预测更好应答。

关键数值与推荐

  • ILD进展定义为12±3个月内预测用力肺活量百分比(%pFVC)下降≥5。
  • 托珠单抗单药治疗占29%,甲氨蝶呤是最常见联合治疗(35%)。

临床怎么用

  • 对系统性硬化症相关间质性肺病、皮肤硬化、指端溃疡及关节炎活动患者,托珠单抗可作为真实世界中的治疗选择,但需监测感染并及时评估疗效。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tocilizumab (TCZ) has shown beneficial effects on interstitial lung disease (ILD) in systemic sclerosis (SSc). We aimed to assess the real-life safety and effectiveness of TCZ on several SSc-related domains using data from a French-Italian multicentre cohort. METHODS: We conducted a retrospective analysis of patients with SSc treated with TCZ across 15 referral centres. The following clinical data were collected at 12 months before TCZ initiation, at baseline and at 12 and 24 months of treatment: modified Rodnan skin score (mRSS), pulmonary function tests, Disease Activity Score in 28 joints using C reactive protein, digital ulcers and cardiac biomarkers. ILD progression was defined as a decline ≥5 in %predicted forced vital capacity (%pFVC) over 12±3 months. RESULTS: 197 patients were included (88% female; median age 57 years; median disease duration 9 years); 67% were antitopoisomerase I positive. TCZ monotherapy was used in 29% of cases, methotrexate was the most frequent combined treatment (35%). In SSc-associated ILD, %pFVC declined significantly from -12 months to baseline (81% to 77%; p=0.003). On TCZ introduction, %pFVC stabilised and the proportion of progressors declined from 43% to 24% (p=0.015). Among diffuse cutaneous patients, mRSS decreased significantly at 12 and 24 months. Digital ulcers, arthritis activity and cardiac biomarkers also improved. Infections were the most frequent adverse events (22.8%). TCZ was discontinued in 32% of patients, mainly for inefficacy. Pulmonary arterial hypertension and older age predicted TCZ failure, whereas elevated CRP predicted better response. CONCLUSIONS: In this large real-life cohort, TCZ was safe and associated with consistent benefits across different domains, supporting its role as a potential disease-modifying treatment in selected patients with SSc.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Buonsante G, De Luca G, Marazzi E, et al. Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study. RMD Open. 2026. PMID: 42264879. doi:10.1136/rmdopen-2025-006688

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。